Clinical Trials at Winship Cancer Institute of Emory University
As of September 2026, 30 paid clinical trials are recruiting at Winship Cancer Institute of Emory University, located at 1365C CLIFTON RD NE, SUITE C2056, ATLANTA, GA 30322-1013, phone (404) 778-1900 in Atlanta, Georgia. Active studies at this site cover conditions such as Multiple Myeloma, Breast Cancer and Sickle Cell Disease. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
30 clinical trials at Winship Cancer Institute of Emory University
·Clear filters·Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
DALY II USA/ MB-CART2019.1 for DLBCL
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
SynKIR-310 for Relapsed/Refractory B-NHL
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Personalized Autologous Transplant for Multiple Myeloma
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Common conditions studied in Atlanta
- Multiple Myeloma (28 active studies)
- Breast Cancer (21 active studies)
- Sickle Cell Disease (19 active studies)
- Schizophrenia (18 active studies)
- Acute Myeloid Leukemia (16 active studies)
- Heart Failure (15 active studies)
Leading research sponsors in Atlanta
- Emory University
- National Cancer Institute (NCI)
- AstraZeneca
- Eli Lilly and Company
- Children's Oncology Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Atlanta?
There are approximately 1,468 recruiting clinical trials in Atlanta, Georgia listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Atlanta pay participants?
Most recruiting trials in Atlanta compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Atlanta?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Atlanta?
The most common conditions under active study in Atlanta include Multiple Myeloma (28), Breast Cancer (21), Sickle Cell Disease (19), Schizophrenia (18), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Atlanta?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Atlanta on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Atlanta?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Atlanta?
Recruiting research sites in Atlanta include Emory University, Emory University Hospital/Winship Cancer Institute, Emory University Hospital Midtown, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Atlanta right now?
The largest active categories in Atlanta are Cancer & tumors (450), Cardiovascular (102), Neurology & pain (80). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Winship Cancer Institute of Emory University?
Winship Cancer Institute of Emory University is located at 1365C CLIFTON RD NE, SUITE C2056, ATLANTA, GA 30322-1013. Use the Google Maps link in the intro above to get directions.
How do I contact Winship Cancer Institute of Emory University?
You can reach Winship Cancer Institute of Emory University by phone at (404) 778-1900. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.